2017

Treatment combinations for pancreatic neuroendocrine tumors
news

A new paper has recently been released in Digestion: International Journal of Gastroenterology that reviewed previously reported European trials. These trials specifically aimed at the treatment of advanced pancreatic neuroendocrine tumors outlined several combinations of chemotherapy drugs used to help with progression free survival (PFS). Pancreatic neuroendocrine tumors (PNETS) are still relatively rare in the umbrella of all gastroenteropancreatic tumors (GEP-NETS or just NETS) and certainly amongst pancreatic lesions in general.

Part Eleven: In front of the eight ball
PRRT & Me

So, it’s been a ridiculously long time since I posted and for that, I am sorry. I meant to update in May as a one-year anniversary of my first round of treatment and I was still slogging through some side effects. If you remember from the last time, I posted about my third round of treatment being a doozy. It was, and maybe, still is. Let me explain. The double

Expanded Access to PRRT in the United States
news

We have exciting news in regards to Peptide Receptor Radionuclide Therapy (PRRT) therapy in the United States. Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial recruitment has been completed, this expanded access therapeutic protocol aims to allow patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy to access the investigational product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to

Mindful Zebra: My Skin Is Telling Me What?
mindful zebra

Hey, good looking, have you been noticing subtle changes with your skin? You might want to get your cute booty to the skin doctor ASAP. Patients living with neuroendocrine cancers including carcinoid are frequently familiar with two of the classic symptoms of the disease including flushing and diarrhea. Subtle, often unrecognized symptoms that are often associated with isolated benign diseases can sometimes run concurrent with patients living with neuroendocrine and carcinoid

Felicia Temple: The Voice
news

It’s not often that we have a reason to discuss reality television shows here on Northwoods NETS, but, we have a notable exception right now. The Voice contestant, Felicia Temple, 28, is also a neuroendocrine tumor patient. An amazing vocalist and songwriter, Ms. Temple was diagnosed with a appendiceal neuroendocrine tumor last year. A registered RN, she underwent surgery and six rounds of chemo before her doctor declared her NED. She